Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05905705 · ClinicalTrials.gov registry record

Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

A clinical trial of Treatment-Resistant Depression, sponsored by Washington University School of Medicine.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT05905705 is a study of Treatment-Resistant Depression that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 50 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05905705, a study of Treatment-Resistant Depression, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

Interventions

  • DIAGNOSTIC_TEST Electroencephalography (EEG)
  • DIAGNOSTIC_TEST Quantitative Measurements of Sleep Microstructure

Study Locations (1)

Missouri

  • Washington University School of Medicine/Barnes-Jewish Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-03-07
Est. Completion 2027-07-31

What the Registry Record Tells You About NCT05905705

The ClinicalTrials.gov registry entry for NCT05905705 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Electroencephalography (EEG) is the first listed.

NCT05905705 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05905705 about?

NCT05905705 is a clinical study titled "Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy". Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

What is the current status of trial NCT05905705?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-03-07. Estimated completion is 2027-07-31.

What conditions does trial NCT05905705 study?

This clinical trial studies the following conditions: Treatment-Resistant Depression.

What interventions are being tested in trial NCT05905705?

The interventions under investigation include: Electroencephalography (EEG) (DIAGNOSTIC_TEST), Quantitative Measurements of Sleep Microstructure (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05905705?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05905705 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Treatment-Resistant Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.